Assertio Therapeutics Inc

Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. Its commercial portfolio of branded products focuses on the following areas: neurology, hospital, and pain and inflammation. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Assertio Therapeutics Inc reports stellar Q4 performance and growth outlook

Assertio Therapeutics Inc (ASRT) delivered a robust Q4 performance with significant revenue and profit growth, despite facing challenges like supply issues.
The company's strategic focus on marketing, product development, and business expansion highlights a commitment to long-term success and shareholder value.
With a positive outlook for 2023 and a strong foundation in place, ASRT is poised for continued growth and value creation in the pharmaceutical market.

Assertio Therapeutics Inc (ASRT) reports robust Q1 results and raises 2023 guidance

Assertio Therapeutics Inc (ASRT) demonstrated solid financial performance in Q1 2023, with strong sales growth and improved profitability.
The company's strategic execution and upcoming acquisitions signal a positive outlook for future growth and expansion.
While facing integration challenges and market competition, Assertio's focus on product sales and operational efficiency bodes well for sustained success.

Assertio Therapeutics reports strong Q2 growth amidst generic competition

Assertio's Q2 performance showcased growth driven by key products and the acquisition of Spectrum Pharmaceuticals, positioning the company for future success.
While facing challenges from generic competition and operational expenses, Assertio remains focused on defending market share and creating shareholder value.
Management's confidence in overcoming short-term obstacles underscores a proactive approach to navigating market dynamics and driving growth.

Assertio Therapeutics Inc reports resilient Q3 performance amidst challenges

Assertio Therapeutics Inc navigated challenges in Q3 2023 with resilience, reporting positive financial metrics and improved liquidity.
New management changes and a focus on market access signal the company's commitment to driving growth and optimizing operations.
Despite lower sales for certain products, Assertio's strategic initiatives and financial performance position it well for future opportunities.
Analyst inquiries during the call highlighted areas for improvement and growth, indicating a proactive approach to addressing market dynamics.

Assertio Therapeutics reports robust Q4 results and outlines growth plans

Assertio Therapeutics Inc (ASRT) demonstrated strong financial performance in Q4 2023, driven by robust sales and positive EBITDA.
The company's strategic focus on Rolvedon's growth, profitability optimization, and future acquisitions positions it well for continued success.
While facing challenges from generic competition and operational issues, Assertio is poised to capitalize on growth opportunities and drive value creation.

Assertio Therapeutics Inc meets Q1 targets, eyes growth opportunities

Assertio Therapeutics Inc's Q1 2024 showcased strong sales performance, cost management, and cash generation. Despite challenges in generic competition and CEO transition, the company remains focused on growth opportunities.

Assertio Therapeutics reports solid Q2 results and projects growth

Assertio Therapeutics Inc (ASRT) demonstrated financial stability, growth potential, and resilience in the face of market challenges during Q2 2024.
The company's strategic focus on key products like Rolvedon and effective cost management strategies position it well for future success and profitability.
Maintaining guidance for 2024 and leveraging opportunities for growth underscore Assertio's commitment to delivering value to shareholders and stakeholders.

Assertio Therapeutics reports stable Q3 performance amid ROLVEDON transition

Assertio Therapeutics demonstrated stable financial performance and operational efficiency in Q3 2024, positioning the company for growth amidst challenges.
The company's focus on ROLVEDON and governance enhancements signal a strategic shift towards innovation and stakeholder value creation.
While facing challenges such as declining product sales and financial constraints, Assertio remains resilient and poised to capitalize on opportunities for growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Assertio Holdings, Inc. (NASDAQ:ASRT ) Q2 2022 Earnings Conference Call August 8, 2022 11:30 AM ET Company Participants Matthew Kreps - Darrow Associates, IR Daniel Peisert - President and CEO Paul Schwichtenberg - SVP and CFO Conference Call Participants Scott Henry - ROTH Capital Mitra Ramgopal - Sidoti Hamed Khorsand - BWS Financial Thomas Flaten - Lake Street Capital Scott Weis - Semco Operator Hello, everyone, and welcome to the Assertio Holdings Q2 Earnings Call. My name is Emily, and I'll be moderating the call today.

Assertio Holdings, Inc. (ASRT) CEO Daniel Peisert on Q2 2022 Results - Earnings Call Transcript

Assertio (ASRT) delivered earnings and revenue surprises of 100% and 11.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Assertio (ASRT) Q2 Earnings and Revenues Top Estimates

Net Product Sales Increase 40% Year-Over-Year, Non-GAAP Adjusted EBITDA Increases to $22.9 million

Assertio Reports Second Quarter 2022 Financial Results

Catalent

ASRT vs. CTLT: Which Stock Is the Better Value Option?

Aethlon Medical

Helix Energy Solutions Group

Transocean

Are you looking for some hot penny stocks to buy this week?

Hot Penny Stocks To Buy? 4 Under $3 To Watch This Week

LAKE FOREST, Ill., July 25, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it will release second quarter 2022 financial results on Monday, August 8, 2022, before the market open. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 11:30 a.m. Eastern Time.

Assertio Holdings, Inc. To Report Second Quarter 2022 Financial Results on Monday, August 8, 2022

Companhia Energetica de Minas Gerais

Gran Tierra Energy

Integrated Media Technology Ltd

Permianville Royalty Trust - Unit

SQL Technologies Corp

Uranium Energy

So, what are the penny stocks to buy today? Consider these seven, a mix of low-priced, small-cap names across a variety of sectors.

7 Top-Rated Penny Stocks to Buy Despite the Downturn

Assertio Holdings' (ASRT) successful execution of its restructuring plan, resulting in significant cost savings, is boosting profits.

Here's Why Assertio Holdings (ASRT) Stock is Up This Year

Chinook Therapeutics

Soleno Therapeutics

Viracta Therapeutics

It is expected that innovation will continue to drive growth in the Medical-Drugs industry in 2022. KDNY, ASRT, VIRX, SLNO may prove to be good additions to one's portfolio.

4 Small Stocks to Bet on in an Upbeat Drugs Industry

Clipper Realty

Consolidated Water

Stocks such as Assertio Holdings (ASRT), Clipper Realty (CLPR) and Consolidated Water (CWCO) should benefit as the dollar strengthens against its key counterparts.

3 Top Stocks That Stand to Gain From a Stronger Dollar

Brookfield Infrastructure Partners L.P.

General Mills

UnitedHealth Group

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our accomplishments from last week.

Beat the Market Like Zacks: Assertio, Brookfield, UnitedHealth, General Mills in Focus

HCI Group

TETRA Technologies

ASRT, TTI and HCI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 10, 2022.

Best Momentum Stocks to Buy for June 10th

LightInTheBox Hld

Safe Bulkers

TransGlobe Energy

Turkcell Iletisim Hizmetleri A.S.

Westport Fuel Systems

In a tough 2022 year for the stock market, these penny stocks could be on the cusp of market-beating gains. The post 7 Best Penny Stocks to Buy Now for Moonshot Potential appeared first on InvestorPlace.

7 Best Penny Stocks to Buy Now for Moonshot Potential

LAKE FOREST, Ill., June 01, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced its participation in the LD Micro Invitational XII Conference on June 7-9, 2022. The conference is being held at the Four Seasons Hotel Westlake Village near Los Angeles, CA. This will be an in-person conference with Assertio presenting on Wednesday, June 8, 2022, at 3:00 pm pacific time in Track 1 and hosting 1:1 meetings with investors throughout the day.

Assertio Holdings, Inc. to Participate in LD Micro Invitational XII Conference

The company has made giant strides in putting its financials in order, getting rid of almost $1B in debt and its net debt has been all but eliminated. We believe more is to come as the company's all-digital business model is very scalable.

Assertio's Phenomenal Turnaround

Assertio Holdings Inc (NASDAQ: ASRT) posted Q1 sales of $35.5 million, up 37% Y/Y, surpassing the consensus of $33.06 million. The increase was primarily driven by higher net pricing on Indocin and the addition of Otrexup.

Assertio Posts Higher Q1 Sales, Profits; Lifts FY22 Adjusted EBITDA Outlook

Assertio Holdings, Inc. (NASDAQ:ASRT ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Max Nemmers - Head, Investor Relations and Administration Daniel Peisert - President & CEO Paul Schwichtenberg - SVP & CFO Conference Call Participants Scott Weis - Semco Capital Operator Good morning and welcome to the Assertio Holdings, Inc. First Quarter 2022 Financial Results Conference Call. All participants will be in listening-only mode.

Assertio Holdings, Inc. (ASRT) CEO Daniel Peisert on Q1 2022 Results - Earnings Call Transcript

Assertio (ASRT) delivered earnings and revenue surprises of 122.22% and 10.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Assertio (ASRT) Surpasses Q1 Earnings and Revenue Estimates

Reaffirms Full Year Net Product Sales and Raises Full Year Non-GAAP Adjusted EBITDA Guidance

Assertio Reports First Quarter 2022 Financial Results

Hudson Technologies

Nokia

Cheap stocks offer a way for risk-taking investors to scale their portfolios quickly. Here are three cheap stocks to buy now.

3 Cheap Stocks to Buy for May 2022

LAKE FOREST, Ill., April 22, 2022 (GLOBE NEWSWIRE) --  Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it will release first quarter 2022 financial results on Monday, May 9, 2022, after the close of markets. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. eastern time.

Assertio Holdings, Inc. to Report First Quarter 2022 Financial Results After the Close of Markets on Monday, May 9, 2022

Company grows the top-line by 7% in Q4 due to strong performances from Indocin, Cambia & Zipsor.

Assertio Holdings: Recent Breakout To Lead To Sustained Gains

DLH Hlds

VAALCO Energy

Assertio Holdings, Inc. (ASRT), VAALCO Energy, Inc. (EGY) and DLH Holdings Corp. (DLHC) have been selected as the breakout stocks for today.

3 Top Breakout Stocks to Invest In for Solid Returns

Collaboration Eases Patient Access to Therapy Collaboration Eases Patient Access to Therapy

Assertio Holdings, Inc. Partners with BlinkRx to Support Healthcare Providers and Patients Utilizing Otrexup® (methotrexate) with a Unique Patient Access Solution

JAKKS Pacific

TimkenSteel

United Fire Group

USA Truck

We have narrowed our search to five small-cap stocks that have provided double-digit returns year to date. These are: USAK, TMST, JAKK, UFCS and ASRT.

News for Assertio Therapeutics Inc Stock (ASRT)